# Contact | Script PT-141 Research Digest

> Contact the editors of Script PT-141, an independent research digest on PT-141 (bremelanotide). Editorial correspondence only — no medical, prescribing, or sales inquiries.

Editorial correspondence about the PT-141 literature — corrections, citations, and questions of scope.

## Editorial correspondence

Use the form below to reach the editors of this PT-141 (bremelanotide) digest. We welcome corrections, suggested citations, and questions about how a claim is sourced or framed. If you believe a study has been summarized inaccurately or a regulatory standing is mislabeled, tell us and point to the source — we will review and amend the record where warranted.

This is an editorial inbox. It is not a clinical, prescribing, or sales channel.

## What we cannot answer

We cannot provide medical advice, dosing guidance, or treatment recommendations, and we will not respond to requests for them. We have no clinicians on staff and no capacity to advise on personal use. Questions about whether PT-141 is appropriate for a given person belong with a licensed healthcare professional who can review that person's history, not with an editorial digest.

We also do not sell, supply, source, or facilitate access to PT-141, bremelanotide, or any other compound, and cannot help with obtaining, pricing, or shipping. Messages seeking to buy or sell will not receive a reply. Correspondence should concern the published literature and this site's coverage of it.

---

A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.